- Home
- PIII vs SLGL Comparison
PIII vs SLGL Comparison
Compare PIII & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PIII
- SLGL
- Stock Information
- Founded
- PIII 2015
- SLGL 1997
- Country
- PIII United States
- SLGL Israel
- Employees
- PIII N/A
- SLGL N/A
- Industry
- PIII Medical/Nursing Services
- SLGL Biotechnology: Pharmaceutical Preparations
- Sector
- PIII Health Care
- SLGL Health Care
- Exchange
- PIII Nasdaq
- SLGL Nasdaq
- Market Cap
- PIII 21.4M
- SLGL 19.3M
- IPO Year
- PIII N/A
- SLGL 2018
- Fundamental
- Price
- PIII $6.69
- SLGL $7.47
- Analyst Decision
- PIII Buy
- SLGL Buy
- Analyst Count
- PIII 2
- SLGL 1
- Target Price
- PIII $16.25
- SLGL $40.00
- AVG Volume (30 Days)
- PIII 4.0K
- SLGL 25.1K
- Earning Date
- PIII 08-06-2025
- SLGL 08-15-2025
- Dividend Yield
- PIII N/A
- SLGL N/A
- EPS Growth
- PIII N/A
- SLGL N/A
- EPS
- PIII N/A
- SLGL N/A
- Revenue
- PIII $1,485,192,000.00
- SLGL $12,103,000.00
- Revenue This Year
- PIII N/A
- SLGL N/A
- Revenue Next Year
- PIII $6.01
- SLGL $31.17
- P/E Ratio
- PIII N/A
- SLGL N/A
- Revenue Growth
- PIII 9.79
- SLGL 603.66
- 52 Week Low
- PIII $6.00
- SLGL $3.34
- 52 Week High
- PIII $32.54
- SLGL $16.50
- Technical
- Relative Strength Index (RSI)
- PIII 49.62
- SLGL 54.46
- Support Level
- PIII $6.00
- SLGL $7.02
- Resistance Level
- PIII $6.37
- SLGL $7.48
- Average True Range (ATR)
- PIII 0.23
- SLGL 0.34
- MACD
- PIII 0.10
- SLGL 0.01
- Stochastic Oscillator
- PIII 93.24
- SLGL 45.39
About PIII P3 Health Partners Inc.
P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.